Jiang Zhi-min, Wei Ying, Zhang Yuan-dong, Zhou Si-wei, Yang Qiong, Xie De-rong
Department of Oncology, The Sun Yat-sen Memorial Hospital, Guangzhou 510120, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Jun;16(6):534-7.
To compare efficacy of different adjuvant chemotherapy regimens for stage II-III gastric cancer after D2 gastrectomy in Asian patients.
Associated literatures were searched through electronic databases and hand-searching. Prospective randomized clinical trials (RCTs) comparing adjuvant chemotherapy after D2 gastrectomy with surgery alone were included in the study. Overall survival and disease-free survival were chosen as the endpoints. Relative hazard was analyzed by Bucher adjusted indirect comparison.
Two RCTs were selected, including comparison between S-1 versus surgery alone and comparison between XELOX versus surgery alone. There was no statistical difference in overall survival between the two regimens (HR=0.94, 95%CI:0.62-1.44, P=0.79). The recurrence risk of S-1 was slightly higher as compared to XELOX, but no statistical difference was found (HR=1.11, 95%CI:0.80-1.53, P=0.54).
The adjuvant chemotherapy with S-1 is similar to XELOX for stage II-III gastric cancer after D2 gastrectomy in Asian patients.
比较亚洲患者D2胃切除术后不同辅助化疗方案对II-III期胃癌的疗效。
通过电子数据库检索和手工检索相关文献。纳入比较D2胃切除术后辅助化疗与单纯手术的前瞻性随机临床试验（RCT）。选择总生存期和无病生存期作为终点。采用Bucher校正间接比较分析相对风险。
选择了两项RCT，包括S-1与单纯手术的比较以及XELOX与单纯手术的比较。两种方案的总生存期无统计学差异（HR=0.94，95%CI：0.62-1.44，P=0.79）。与XELOX相比，S-1的复发风险略高，但无统计学差异（HR=1.11，95%CI：0.80-1.53，P=0.54）。
对于亚洲患者D2胃切除术后的II-III期胃癌，S-1辅助化疗与XELOX相似。
